[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100069294":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":7,"responsibleParty":17,"collaborators":7,"id":19,"slug":20,"hasResults":21,"nctId":22,"briefTitle":23,"officialTitle":24,"acronym":7,"eligibilityCriteria":25,"healthyVolunteers":21,"sex":26,"minAge":27,"maxAge":28,"enrollmentInfo":29,"targetDuration":7,"studyType":32,"phases":33,"briefSummary":35,"conditions":36,"keywords":38,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":7},{"fullName":5,"class":6},"Novartis","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Oxcarbazepine",[13],{"name":14,"affiliation":15,"role":16},"Celso Arango, MD","Hospital Gregorio Marañón,Madrid, Spain","PRINCIPAL_INVESTIGATOR",{"type":18,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100069294","phase-4-the-efficacy-and-safety-of-oral-oxcarbazepine-300-1200-mgday-as-adjuvant-therapy-in-the-treatment-of-adolescents-with-impulsivity-and-aggressive-behavior-in-conduct-disorder-this-study-is-not-being-conducted-in-the-united-states-100069294",false,"NCT00154362","The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg\u002FDay as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.","A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg\u002FDay) as Adjuvant Therapy for Impulsivity and Aggressive Behavior in Conduct Disorders in Adolescents","Inclusion Criteria:\n\n* History of conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified\n* Score \\>8 on the Impulsivity Rating Scale\n\nExclusion Criteria:\n\n* Other serious medical or psychiatric conditions excluding conduct disorder, oppositional defiant disorder, and disruptive behavior disorder not otherwise specified\n* Treatment with antiepileptic medications\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","6 Years","16 Years",{"count":30,"type":31},50,"ACTUAL","INTERVENTIONAL",[34],"PHASE4","Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.",[37],"Conduct Disorder",[39],"Oxcarbazepine, conduct disorder, adolescents","COMPLETED","2011-11-22",{"date":43,"type":44},"2011-11-24","ESTIMATED",{"date":46,"type":7},"2003-04",{"date":48,"type":31},"2004-10",{"name":5,"class":6}]